FDA-approved drug may block resistance to anti-angiogenesis therapySeptember 13, 2017
A Massachusetts General Hospital (MGH) research team has identified a potential strategy for improving the efficacy of angiogenesis inhibitors, drugs that help fight cancer by blocking the formation of new blood vessels. In a follow-up to a study published earlier this year that discovered how anti-angiogenesis treatment can interfere with the immune response against colorectal cancer, the team now describes another pathway that induces an immunosuppressive tumor microenvironment, one that can be blocked with an FDA-approved drug.
"Blocking VEGF signaling - the major target of approved anti-angiogenesis drugs - has shown significant but limited survival benefit for colorectal cancer patients, due to the development of resistance," explains Dai Fukumura, MD, PhD, deputy director of the Edwin L. Steele Laboratories for Tumor Biology in the MGH Department of Radiation Oncology and co-senior author of the current study, which has been published in the online PNAS Early Edition. "By unveiling a previously unknown mechanism of resistance to anti-angiogenic therapy, our findings provide a rapidly translatable strategy to enhancing treatment outcomes."
In their earlier study published in the Journal of Clinical Investigation, the researchers found that angiogenesis inhibitor treatment led to the accumulation of certain innate immune cells - monocytes and neutrophils - in the tumor microenvironment. The early infiltration of a specific subset of cells, called non-classical monocytes, induced the migration of neutrophils and the expression of factors that inhibit the proliferation and function of T cells, blocking the anti-tumor immune response.
While a gene therapy approach to blocking the immunosuppressive pathway identified in the JCI study improved treatment in a mouse model of colorectal cancer, no drug targeting that pathway is currently available, leading the MGH team to search for alternatives. A 2009 study from members of the same team had found that expression of a receptor molecule called CXCR4 and the molecule it binds to, CXCL12, were increased in tumor biopsies from rectal cancer patients treated with anti-VEGF therapy. Since the CXCR4/CXCL12 pathway is known to regulate immune cells, including the more common classical monocytes, the team explored its potential role in the regulation of non-classical monocytes.
After confirming that anti-VEGF therapy increased expression of CXCR4 and CXCL12 in mouse models of colorectal cancer, the team tested the effects of using an FDA-approved CXCR4 inhibitor called AMD3100 or plerixafor to block the pathway. They found that the addition of AMD3100 significantly enhanced the effects of anti-VEGF therapy and alleviated the anti-VEGF-induced reduction in T cells. CXCR4 was found to be expressed primarily on monocytes and neutrophils in the tumor microenvironment, and blocking the pathway with AMD3100 reduced the infiltration of immunosuppressive non-classical monocytes and neutrophils, improving treatment efficacy.
"We anticipate that these novel findings on the immunosuppressive role of non-classical monocytes in colorectal cancer will trigger follow-up studies in other types of cancer, as well as in inflammatory diseases, leading to the development of multiple therapeutic regimens," says Fukumura, an associate professor of Radiation Oncology at Harvard Medical School (HMS).
Rakesh K. Jain, PhD - director of the Steele Labs, Cook Professor of Radiation Oncology (Tumor Biology) at HMS, and co-senior author of the PNAS paper - adds, "While AMD3100 treatment abolished anti-VEGF-induced innate immune cell accumulation, it did not affect basal levels of these important cells, which supports the favorable safety profile of this agent and should facilitate clinical translation."
Support for the study includes National Cancer Institute grants P01-CA080124, R35-CA197743, R01-CA096915 and R01 CA214913; National Institutes of Health grant DP2 OD008780 and Department of Defense grant W81XWH-10-1-0016.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $850 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2017 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."
Massachusetts General Hospital
Related Cancer Articles:
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Is investment in research to develop new treatments the best approach to controlling cancer?
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.
Related Cancer Reading:
The Emperor of All Maladies: A Biography of Cancer
by Siddhartha Mukherjee (Author)
Winner of the Pulitzer Prize, and now a documentary from Ken Burns on PBS, The Emperor of All Maladies is a magnificent, profoundly humane “biography” of cancer—from its first documented appearances thousands of years ago through the epic battles in the twentieth century to cure, control, and conquer it to a radical new understanding of its essence.
Physician, researcher, and award-winning science writer, Siddhartha Mukherjee examines cancer with a cellular biologist’s precision, a historian’s perspective, and a biographer’s passion. The result is an astonishingly... View Details
The Truth about Cancer: What You Need to Know about Cancer's History, Treatment, and Prevention
by Ty M Bollinger (Author)
Cancer touches more lives than you may think. According to the World Health Organization, one out of three women alive today, and one out of two men, will face a cancer diagnosis in their lifetime.
To Ty Bollinger, this isn’t just a statistic. It’s personal. After losing seven members of his family to cancer over the course of a decade, Ty set out on a global quest to learn as much as he possibly could about cancer treatments and the medical industry that surrounds the disease. He has written this book to share what he’s uncovered—some of which may shock you—and to give you... View Details
Anticancer: A New Way of Life
by David Servan-Schreiber MD PhD (Author)
The revolutionary, New York Times bestselling guide to the powerful lifestyle changes that fight and prevent cancer—an integrative approach based on the latest scientific research
“A common-sense blueprint for healthy living.” —Chicago Tribune
“Resonating with cancer support communities and recommended nationwide.” —Los Angeles Times
“Life affirming . . . filled with practical advice.” —The Seattle Times
David Servan-Schreiber was a rising... View Details
The Cancer-Fighting Kitchen, Second Edition: Nourishing, Big-Flavor Recipes for Cancer Treatment and Recovery
by Rebecca Katz (Author), Mat Edelson (Author)
This new and revised edition of the IACP award-winning cookbook brings the healing power of delicious, nutritious foods to those whose hearts and bodies crave a revitalizing meal, through 150 new and updated recipes.
Featuring science-based, nutrient-rich recipes that are easy to prepare and designed to give patients a much-needed boost by stimulating appetite and addressing treatment side effects including fatigue, nausea, dehydration, mouth and throat soreness, tastebud changes, and weight loss. A step-by-step guide helps patients nutritionally prepare for all phases of... View Details
Outside the Box Cancer Therapies: Alternative Therapies That Treat and Prevent Cancer
by Dr. Mark Stengler (Author), Dr. Paul Anderson (Author)
Naturopathic medical doctors Mark Stengler and Paul Anderson focus on the most critical components of Integrative Oncology Care. Using an accessible, case-history approach, they explore the different types of cancer, the causes of cancer, how proper nutrition can help prevent and treat cancer, the most well-studied supplement to use with cancer treatment, cutting-edge therapies (such as intravenous high dose vitamin C and other studied therapies), and natural solutions to common problems (such as the side effects of chemotherapy and radiation). View Details
F*ck Cancer: A totally inappropriate self-affirming adult coloring book (Totally Inappropriate Series) (Volume 4)
by Jen Meyers (Author)
*A portion of the proceeds from this book will be donated to support research dedicated to finding a cure for cancer. Because fuck cancer.
This book is for you.
If you are fighting cancer, this is for you. If your brother, sister, mom, dad, son, daughter, relative, or friend is fighting cancer, this is for you. If you've lost someone to cancer like I have, this is for you. If cancer affects your life in any way, this is for you.
The stress of cancer can feel crushing. But perhaps this book can help you get away from it all, if only for a little... View Details
The Metabolic Approach to Cancer: Integrating Deep Nutrition, the Ketogenic Diet, and Nontoxic Bio-Individualized Therapies
by Dr. Nasha Winters ND FABNO L.Ac Dipl.OM (Author), Jess Higgins Kelley MNT (Author), Kelly Turner (Foreword)
The Optimal Terrain Ten Protocol to Reboot Cellular Health
Since the beginning of the twentieth century, cancer rates have increased exponentially―now affecting almost 50 percent of the American population. Conventional treatment continues to rely on chemotherapy, surgery, and radiation to attack cancer cells. Yet research has repeatedly shown that 95 percent of cancer cases are directly linked to diet and lifestyle. The Metabolic Approach to Cancer is the book we have been waiting for―it offers an innovative, metabolic-focused nutrition protocol that... View Details
Radical Remission: Surviving Cancer Against All Odds
by Kelly A. Turner PhD (Author)
In her New York Times bestseller, Radical Remission: Surviving Cancer Against All Odds, Dr. Kelly A. Turner, founder of the Radical Remission Project, uncovers nine factors that can lead to a spontaneous remission from cancer—even after conventional medicine has failed.
While getting her Ph.D. at the University of California, Berkley, Dr. Turner, a researcher, lecturer, and counselor in integrative oncology, was shocked to discover that no one was studying episodes of radical (or unexpected) remission—when people recover against all odds without the help of... View Details
Cancer: 50 Essential Things to Do: 2013 Edition
by Greg Anderson (Author)
The ground-breaking classic guide to surviving cancer?now completely updated!
Revised and updated for the first time since 1999, this invaluable guide to cancer recovery offers an easily accessible plan for patients and family members. Written by a cancer survivor, the book is an inspiring, action-oriented roadmap for those who choose to adopt a stance of hope and take charge of their diagnosis.
With penetrating insights that bring together more than two decades of scientifically supported research and experience, Anderson reveals a step-by-step holistic action plan... View Details
Keto for Cancer: Ketogenic Metabolic Therapy as a Targeted Nutritional Strategy
by Miriam Kalamian EdM MS CNS (Author), Thomas N. Seyfried (Foreword)
A Comprehensive Guide for Patients and Practitioners
Although evidence supporting the benefits of ketogenic diet therapies continues to mount, there is little to guide those who wish to adopt this diet as a metabolic therapy for cancer. Keto for Cancer fills this need. Inspired by the work of Dr. Thomas N. Seyfried, PhD, nutritionist Miriam Kalamian has written the first book to lay out comprehensive guidelines that specifically address the many challenges associated with cancer, and particularly the deep nutritional overhaul involved with the ketogenic... View Details